DelveInsight's "Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Systemic Lupus Erythematosus, historical and forecasted epidemiology as well as the Systemic Lupus Erythematosus market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Discover Key Insights into the Systemic Lupus Erythematosus Market with DelveInsight's In-Depth Report @ Systemic Lupus Erythematosus Market Size
Key Takeaways from the Systemic Lupus Erythematosus Market Research Report
- The increase in Systemic Lupus Erythematosus Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
- Between EU4 and the UK, Spain accounted for the highest number of diagnosed prevalent cases followed by the UK and Germany.
- The age group most affected by the prevalence of systemic lupus erythematosus is 40-59 years. In 2023, among 7MM, approximately 40% of cases belonged to the 40-59 years age group.
- In 2023, approximately 50% of cases were found to be moderate cases in Spain..
- The leading Systemic Lupus Erythematosus Companies such as GlaxoSmithKline, AstraZeneca, Eli Lilly and Company, Biogen, UCB Pharma/Biogen, Immupharma, Hoffmann-La Roche, Xencor, Idorsia Pharmaceuticals, Bristol-Myers Squibb (Celgene), Resolve Therapeutics, Genentech (Roche), Pfizer, and others.
- Promising Systemic Lupus Erythematosus Pipeline Therapies such as LY3471851, Lupuzor, BIIB059, Dapirolizumab pegol, Gazyva, Cenerimod, and others.
Navigate the complexities of the Systemic Lupus Erythematosus Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Systemic Lupus Erythematosus Market Forecast. Click here to get more insights @ Systemic Lupus Erythematosus Treatment Market
Systemic Lupus Erythematosus Epidemiology Segmentation in the 7MM
- Total Systemic Lupus Erythematosus Diagnosed Prevalent Cases
- Systemic Lupus Erythematosus Age-specific Diagnosed Prevalent Cases
- Systemic Lupus Erythematosus Severity-specific Diagnosed Prevalent Cases
- Systemic Lupus Erythematosus Gender-specific Diagnosed Prevalent Cases
Download the report to understand which factors are driving Systemic Lupus Erythematosus epidemiology trends @ Systemic Lupus Erythematosus Prevalence
Systemic Lupus Erythematosus Marketed Drugs
- BENLYSTA (belimumab): GlaxoSmithKline
BENLYSTA (belimumab), a B-lymphocyte stimulator (BLyS) specific inhibitor, is a fully human monoclonal antibody that binds to soluble BLyS, which is found to be increased in patients with systemic autoimmune diseases like SLE and lupus nephritis (LN). ABy bding BLyS, BENLYSTA inhibits the prolonged survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells. BENLYSTA does not bind B cells directly. The US FDA first approved BENLYSTA for the treatment of active systemic lupus erythematosus; it is the first and only approved biologic for both SLE and LN in more than 50 years, including for the pediatric population. It was first approved by the US FDA in 2011.
- SAPHNELO (anifrolumab): AstraZeneca
SAPHNELO (anifrolumab) is a first in class, fully human monoclonal antibody that binds to subunit 1 of the type I interferon (IFN) receptor, blocking the activity of type I IFN. Type I IFNs, such as IFN-alpha, IFN-beta and IFN-kappa, are cytokines involved in regulating the inflammatory pathways implicated in SLE. The majority of adults with SLE have increased type I IFN signaling, which is associated with increased disease activity and severity. SAPHNELO is approved to treat systemic lupus erythematosus in more than 60 countries worldwide including the US, EU and Japan, with reviews ongoing in other countries.
Systemic Lupus Erythematosus Emerging Drugs Profile
- Cenerimod: Idorsia Pharmaceuticals/Viatris
Cenerimod is a highly selective sphingosine-1-phosphate receptor 1 (S1P1) receptor modulator, given as an oral once-daily tablet. While the cause of SLE is not fully known, T and B-lymphocytes are considered the key immune cells playing a role in the development of SLE. T and B-lymphocytes have a cell surface receptor called S1P1. These receptors enable T and B-lymphocytes to detect the signaling molecule S1P – sphingosine 1 phosphate – which is responsible for lymphocyte trafficking from the lymph nodes to the circulation. By binding to S1P1 receptors, a receptor modulator can trigger the internalization of those receptors. This effectively blinds T and B lymphocytes to the S1P gradient, thereby holding them in the lymph nodes and reducing autoreactive T and B cells in the circulation and, consequently, also in the tissues. In December 2017, the US FDA designated the investigation of cenerimod for the treatment of SLE as a fast-track development program. Currently it is in Phase III of its clinical development.
- Litifilimab: Biogen
Litifilimab is a humanized IgG1 monoclonal antibody (mAb) targeting BDCA2 and is being investigated for the potential treatment of SLE and cutaneous lupus erythematosus (CLE). BDCA2 is a receptor that is predominantly expressed on a subset of human immune cells called Plasmacytoid Dendritic Cells (pDCs). The binding of litifilimab to BDCA2 has been shown to reduce the production of pro-inflammatory molecules by pDCs, including type-I interferon (IFN-I) as well as other cytokines and chemokines. Currently it is in Phase III of its clinical development.
Get In-Depth Knowledge on Systemic Lupus Erythematosus Market Trends and Forecasts with DelveInsight @ Systemic Lupus Erythematosus Treatment Market
Systemic Lupus Erythematosus Treatment Market
Systemic Lupus Erythematosus treatment include NSAIDs and antimalarial agents, which are the first-line therapies formild SLE. In addition, glucocorticoids and cytotoxic or immunosuppressive agents—such as azathioprine, mycophenolatemofetil, cyclophosphamide, cyclosporine, and methotrexate —are used for SLE with organ involvement. The current market possesses two approved products, Benlysta (belimumab) and Saphnelo (anifrolumab-fnia).
Systemic Lupus Erythematosus Market Dynamics
The Systemic Lupus Erythematosus market dynamics is anticipated to change in the coming years owing to the improvement in the research and development activities for efficient treatment options to be available in the market. The launch of emerging therapies is expected during the forecast period of 2024–2034. Few major key players of the emerging therapy market of SLE includes GlaxoSmithKline, AstraZeneca, Eli Lilly and Company, Biogen, UCB Pharma/Biogen, Immupharma, Hoffmann-La Roche, Xencor, Idorsia Pharmaceuticals, Bristol-Myers Squibb (Celgene), Resolve Therapeutics, Genentech (Roche), Pfizer, and others
Gain a strategic edge in the Systemic Lupus Erythematosus Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Systemic Lupus Erythematosus Market Forecast. Click here to lead in advancements @ Systemic Lupus Erythematosus Clinical Trials Assessment
Scope of the Systemic Lupus Erythematosus Market Research Report
- Coverage- 7MM
- Systemic Lupus Erythematosus Companies- GlaxoSmithKline, AstraZeneca, Eli Lilly and Company, Biogen, UCB Pharma/Biogen, Immupharma, Hoffmann-La Roche, Xencor, Idorsia Pharmaceuticals, Bristol-Myers Squibb (Celgene), Resolve Therapeutics, Genentech (Roche), Pfizer, and others.
- Systemic Lupus Erythematosus Pipeline Therapies- LY3471851, Lupuzor, BIIB059, Dapirolizumab pegol, Gazyva, Cenerimod, and others.
- Systemic Lupus Erythematosus Market Dynamics: Systemic Lupus Erythematosus Market Drivers and Barriers
- Systemic Lupus Erythematosus Market Access and Reimbursement, Unmet Needs and Perspectives
Table of Content
1. Key Insights
2. Systemic Lupus Erythematosus Executive Summary
3. Systemic Lupus Erythematosus Competitive Intelligence Analysis
4. Systemic Lupus Erythematosus: Market Overview at a Glance
5. Systemic Lupus Erythematosus: Disease Background and Overview
6. Patient Journey
7. Systemic Lupus Erythematosus Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Systemic Lupus Erythematosus Unmet Needs
10. Key Endpoints of Systemic Lupus Erythematosus Treatment
11. Systemic Lupus Erythematosus Marketed Products
12. Systemic Lupus Erythematosus Emerging Therapies
13. Systemic Lupus Erythematosus: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Systemic Lupus Erythematosus Market Outlook
16. Access and Reimbursement Overview
17. KOL Views
18. Systemic Lupus Erythematosus Market Drivers
19. Systemic Lupus Erythematosus Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage
